Oxatomide Inhibits Interleukin-8 Release from Respiratory Epithelial Cells*

Total Page:16

File Type:pdf, Size:1020Kb

Oxatomide Inhibits Interleukin-8 Release from Respiratory Epithelial Cells* ORIGINAL CONTRIBUTION Oxatomide inhibits Interleukin-8 release from respiratory epithelial cells* 1 1 1 1 Hideyuki Kawauchi , Noriaki Aoi , Ichiro Morikura , Takafumi Fuchiwaki , Rhinology Online, Vol 1: 50 - 56, 2018 1 1 1 1 Yasuhiko Shimizu , Kanako Shimizu , Yukie Hotta , Qu Infei , Takaya http://doi.org/10.4193/RHINOL/18.026 Yamada2, Emmanuel Prokopakis3 *Received for publication: 1 Department of Otorhinolaryngology, Shimane University, Faculty of Medicine, Izumo City, Japan May 25, 2018 2 Department of Experimental Animals, Interdisciplinary Center for Science Research, Organization for Research, Shimane Accepted: May 29, 2018 University, Izumo city, Japan 3 Department of Otolaryngology, University of Crete School of Medicine, Heraklion, Crete, Greece Abstract Background: Oxatomide, a H1-receptor antagonist, exerts besides its well-known anti-allergic potential an array of anti-inflam- matory activities. We wondered whether oxatomide might influence the release of IL-8 from human epithelial cells activated with agonists of TLR2, which mainly expresses on airway epithelial cells. Methodology: We used the human lung epithelial cell line A549 and primary Human nasal epithelial cell line for our in vitro stu- dies. IL-8 releases from these cell lines were determined by IL-8 enzyme immunoassay. NF-kB was analysed by Luciferase reporter assay. Confluent epithelial cell monolayer were pre-incubated with oxatomide for 30 min and afterwards activated with lipopro- tein as a TLR2 agonist for 24 h. Results: Epithelial cells stimulated with lipoprotein showed a significantly increased release of IL-8. Pre-incubation with oxatomi- de diminished the IL-8 release from cells activated with lipoprotein in a significant manner. Furthermore, activity of the NF-kB was determined by luciferase reporter assy. Besides, oxatomide inhibits expression of MIP2, a homologue of human IL-8, and neutrop- hilic infiltration in nasal membrane of mice intranasally exposed with lipoprotein. These results suggest that oxatomide reduced the release of IL-8 from respiratory epithelial cells stimulated with lipoprotein. Conclusion: Therefore, oxatomide might exert anti-inflammatory effects beyond its H1-receptor antagonistic activity in the course of inflammatory respiratory tract disorders such as acute bacterial rhinitis. Key words: H1-receptor antagonists, IL-8, nasal epithelial cell, NF-kB Introduction locytes, T cells (4) and the adhesion of eosinophils to endothelial Oxatomide, a carboxylated metabolite of hydroxizine, belongs cells was inhibited (5). It has been shown that the production of to the new generation of H1-receptor antagonists (1). A positive newly generated pro-inflammatory mediators such as reactive therapeutic effect of oxatomide has been shown in allergic rhi- toxic oxygen radicals and lipid mediators from eosinophils (6), noconjunctivitis, chronic urticaria, and pollen-associated asthma basophils and mast cells (7) was counter-regulated by oxatomide. (2,3). There has also been an accumulation of evidence that oxa- Besides, LTD4 in middle ear of chinchillas with otitis media with tomide shows some anti-inflammatory activities unrelated to its effusion was reported to be suppressed by oxatomide (8). It has histamine antagonism, e.g. the chemotactic activity of granu- also been shown that epithelial cells play a crucial role during Abbreviations used in this paper: IL, Interleukin; CD, Clusters of differentiation; TRL, Toll-like receptor; FCS, Fetal calf serum; HNECs, Human nasal epi- thelial cells; HPV-16, Human papillomavirus 16; Ig, Immunoglobulin; ikBα, Inhibitor kBα; RT, Reverse transriptase; ELISA, Enzyme-linked immunosorb- ent assay; NF-kB, Nuclear Factor-kB; i.n., Intranasally; i.g., Intragastric. 50 Oxatomide inhibits Interleukin-8 release acute inflammatory and infectious processes by secreting µg/ml streptomycin, 100 IU/ml penicillin and 20 mmol/l sodium interleukin-8 (IL-8) (9-12). The multifactorial pro-inflammatory hydrogen carbonate. Normal human nasal tissues (500 mg) were cytokine IL-8, a member of the chemokine super-gene family obtained from two patients with chronic sinusitis after receiving (13), has chemotactic activity toward neutrophils as well as T informed consent from the patients. HNECs were transfected lymphocytes (14). In addition, neutrophils are activated by IL- with human papillomavirus 16 (HPV-16) E6 and E7 open reading 8,enhanced expression of Clusters of differentiation (CD) 11b/ frames. These cells were designated HNEC-1 and HNEC-2, res- CD18, transendothelial migration, generation of reactive oxygen pectively, and used between passages 50 and 60. HEK293 and products and exocytosis (15). As a direct consequence of this po- U937 as a human monocytes were obtained from ATCC. tent neutrophil-activating potential, IL-8 plays a major role in the pathogenesis of many acute inflammatory reactions, including Cell culture conditions acute rhinitis (16,17). Epithelial cells recognize microbial pathogens A549 cells, HNEC-1 and HNEC-2 were cultured at 370C in a water- by a set of germ line-encoded receptors that are referred to as saturated atmosphere containing 5% CO2. Only cell preparati- pattern-recognition receptors. Toll-like receptors (TLRs) function ons with a viability greater than 95%, determined by a trypan as the major epithelial pattern-recognition receptors in recog- blue exclusion test, were used. The buffers and cell media were nition of a pathogen-associated molecular patterns (18). Activa- prepared using pyrogen-free water. Confluent A549, HNEC-1 and tion of TLRs, in turn, leads to induction of direct antimicrobial HNEC-2 monolayers (105 cells) were cultured in 1 mL RPMI-1640 effector pathways that can result in elimination of the invading (10% FCS [v/v]) with antibiotics in 24-well plastic tissue culture pathogens (19). Activation of TLRs also induces the expression of plates (Costar, Cambridge, MA, USA). Confluent monolayers were co-stimulatory molecules and the release of IL-8 that instruct pre-incubated with oxatomide (0.01-10 μg/ml) for 30 min. After the acquired immune response (20). To date, 10 members of the pretreatment, the cells were washing with PBS twice. The range human TLR family have been cloned. Among these, TLR2 has of doses used, 0.01-10 µg/ml, corresponds to the physiologi- been shown to mediate responses to a variety of Gram-positive cal plasmatic concentration range of oxatomide. After 24 h of products, including peptidoglycan, lipoprotein, lipoteichoic acid culture, the cell supernatants were collected and stored at -70°C and lipoarabinomannan. It is clear that TLR2 plays a crucial role until IL-8 determination. in host defense against both Gram-positive and -negative bacte- ria (21,22)]. Interestingly, in the upper respiratory tract, it has been Mice reported that TLR2 is expressed dominantly in epithelial cells (23). C57BL/6 mice were purchased from Japan SLC (Shizuoka, Japan). We wondered whether IL-8 production by human epithelial cells The mice were bred in our institute under specific pathogen-free stimulated with lipoprotein via TLR2 might also be influenced by conditions. Eight- to 10-week-old female mice were used for the the H1-receptor antagonist oxatomide. We used the human pul- experiments. monary type II epithelial cell line A549 and primary Human nasal epithelial cells (HNECs) for our in vitro study. We also assessed Reverse transcription-PCR the in vivo role of oxatomide in a murine acute rhinitis model. Total cellular RNA from A549, HNEC-1, HNEC-2 and U937 was extracted with RNAzol B (Tel-Test, Friendswood, TX, USA) using Methods a single-step isolation method (25,26) according to the manufac- Reagents turer's recommendation. RNase-free DNase (Takara Biochemi- Synthetic Lipid A was provided by Ono Pharmaceutics. Synthetic cals, Shiga, Japan) was used to remove genomic DNA based on lipoprotein (palmitoyl-Cys(RS)-2,3-di(palmitoyloxy)-propyl)-Ala- methods described previously (27). Two micrograms of extracted Gly-OH)) was provided by Bachem (Bubendorf, Switzerland). RNA was reverse-transcribed into first-strand cDNA at 42°C for Anti-phospho- Inhibitor kBa (ikBa) mAb and anti-ikBa poly- 40 min using 100 U/ml of reverse transcriptase (RT) (Takara clonal Ab were obtained from New England Biolabs (Beverly, Biomedicals, Shiga, Japan) and 0.1 µM oligo(dT) adapter primer MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), (Takara Biomedicals, Shiga, Japan) in a 50-µl reaction mixture. respectively. Anti-murine MIP-2 monoclonal antibody was PCR amplification of cDNA was performed using oligonucle- purchased from Genzyme-Thecne (Techne, AN'ALYZA immuno- otide primers specific for TLR1 (Sense: 5'-AGTTGTCAGCGATG- assay system; Genzyme). TGTTCGG-3' Antisense: 5'-GATCAAGTACCTTGATCCTGGG-3', TLR2 (Sense: 5'-GGCTTCTCTGTCTTGTGACC-3' Antisense: 5'-GGGCTT- Cells GAACCAGGAAGAC G-3'), TLR3 (Sense: 5'-AGCCACCTGAAGTTG- Cells of the human A549, pulmonary epithelial cell line (ATCC ACTCAGG-3' Antisense: 5'-CAGTCAAATTCGT GCAGAAGGC-3'), CCL 185, Rockville, MD, USA) show features of type II alveolar TLR4 (Sense: 5'-TTGTATTCAAG GTCT GGCTGG-3' Antisense: epithelial cells and produce surfactants (24). The cells were grown 5'-GCAAC CTTTGAAACTCAAGCC-3'), TLR5 (Sense: 5'-AGC- in FK12 medium containing 10% (v/v) fetal calf serum (FCS), 100 CATCTG ACTGCATTAAGG-3' Antisense: 5'-GACTTCCTCTTCAT- 51 Kawauchi et al. CACAACC-3'), TLR6 (Sense: 5'-CCTG GGAGGTAAACATCTGA-3' Antisense: 5'-CCCTCAACCACATAGAAACGA-3'), TLR7 (Sense: 5'-GATAACAATGTCACAGC CGTCC-3' Antisense: 5'-GTTCCTG- GAGTTTGTTGATGTTC-3'),
Recommended publications
  • T Cell Binding to Activated Dendritic Cells Cutting Edge
    Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang and Sam T. Hwang This information is current as J Immunol 2001; 167:4791-4795; ; of September 27, 2021. doi: 10.4049/jimmunol.167.9.4791 http://www.jimmunol.org/content/167/9/4791 Supplementary http://www.jimmunol.org/content/suppl/2001/10/11/167.9.4791.DC1 Downloaded from Material References This article cites 32 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/167/9/4791.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. ● Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang, and Sam T. Hwang1 DC. In the periphery, activated, Ag-bearing DC may bind to cog- The binding of a T cell to an Ag-laden dendritic cell (DC) is a nate effector memory T cells (mTC).
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Mechanism of Macrophage-Derived Chemokine/CCL22 Production by Hacat Keratinocytes
    C Yano, et al Ann Dermatol Vol. 27, No. 2, 2015 http://dx.doi.org/10.5021/ad.2015.27.2.152 ORIGINAL ARTICLE Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes Chizuko Yano, Hidehisa Saeki1, Mayumi Komine2, Shinji Kagami3, Yuichiro Tsunemi4, Mamitaro Ohtsuki2, Hidemi Nakagawa Department of Dermatology, The Jikei University School of Medicine, 1Department of Dermatology, Nippon Medical School, Tokyo, 2Department of Dermatology, Jichi Medical University, Shimotsuke, 3Department of Dermatology, Kanto Central Hospital, 4Department of Dermatology, Tokyo Women’s Medical University, Tokyo, Japan Background: CC chemokine ligand 17 (CCL17) and CCL22 27(2) 152∼156, 2015) are the functional ligands for CCR4. We previously reported that inhibitors of nuclear factor-kappa B and p38 mi- -Keywords- togen-activated protein kinase (p38 MAPK), but not of ex- Chemokine CCL22, Chemokine CCL17, Epidermal growth tracellular signal-related kinase (ERK), inhibited tumor ne- factor receptor, HaCaT keratinocytes crosis factor (TNF)-α- and interferon (IFN)-γ-induced pro- duction of CCL17 by the human keratinocyte cell line, HaCaT. Further, an inhibitor of epidermal growth factor re- INTRODUCTION ceptor (EGFR) enhanced the CCL17 production by these keratinocytes. Objective: To identify the mechanism under- The macrophage-derived chemokine (MDC)/CC chemo- lying CCL22 production by HaCaT cells. Methods: We inves- kine ligand 22 (CCL22) is one of the functional ligands for tigated the signal transduction pathways by which TNF-α CC chemokine receptor 4 (CCR4) and is a chemoattractant and IFN-γ stimulate HaCaT cells to produce CCL22 by add- for the CCR4-expressing cells such as Th2 cells. We and ing various inhibitors.
    [Show full text]
  • Differential Expression of Interferon-Γ and Chemokine Genes
    Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Owens et al. Owens et al. Journal of Neuroinflammation 2013, 10:56 http://www.jneuroinflammation.com/content/10/1/56 Owens et al. Journal of Neuroinflammation 2013, 10:56 JOURNAL OF http://www.jneuroinflammation.com/content/10/1/56 NEUROINFLAMMATION RESEARCH Open Access Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Geoffrey C Owens1,7*, My N Huynh1, Julia W Chang1, David L McArthur1, Michelle J Hickey2, Harry V Vinters2,3, Gary W Mathern1,4,5,6† and Carol A Kruse1,6† Abstract Background: Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children, that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy. Methods: Quantitative polymerase chain reactions measured the relative expression of 84 genes related to inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method.
    [Show full text]
  • H1-Antihistamines for Chronic Spontaneous Urticaria: an Abridged Cochrane Systematic Review
    H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review Sharma, Maulina , Bennett, C. , Carter, Ben and Cohen, Stuart N. Author post-print (accepted) deposited by Coventry University’s Repository Original citation & hyperlink: Sharma, Maulina , Bennett, C. , Carter, Ben and Cohen, Stuart N. (2015) H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review . Journal of the American Academy of Dermatology, volume 73 (4): 710-716 http://dx.doi.org/10.1016/j.jaad.2015.06.048 DOI 10.1016/j.jaad.2015.06.048 ISSN 0190-9622 ESSN 1097-6787 Publisher: Elsevier NOTICE: this is the author’s version of a work that was accepted for publication in Journal of the American Academy of Dermatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of the American Academy of Dermatology, [VOL 73, ISSUE 4, (2015)] DOI: 10.1016/j.jaad.2015.06.048 © 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.
    [Show full text]
  • Tor Amendment Tagoor Laboratories Private Limited
    ToR Amendment Tagoor Laboratories Private Limited ANNEXURE – I Details of Products as per Granted ToR and Amendment Required Production Capacity S. Ton /Month Therapeutic Product Name No As per Amendment category granted ToR Required 1 Abacavir sulfate 2.0 2.0 Anti HIV 2 Amitriptyline 5.0 10.0 Antidepressant 3 Atrovastatin Calcium 5.0 5.0 Hypercholesterolemia 4 Bupropion 5.0 5.0 Anti depressant 5 carisoprodol 2.0 2.0 Muscle Relaxant 6 Clopidogrelbisulfate 5.0 5.0 Antithrombotic 7 Cyclobenzaprine HCl 5.0 5.0 Muscle relaxant 8 Cyproheptadine HCl 5.0 10.0 Anti allergic 9 Desloratadine 5.0 5.0 Antihistamine 10 Domperidone 20.0 30.0 Anti emetic 11 Domperidone maleate 2.0 2.0 Anti emetic 12 Donepezil HCl 1.0 1.0 Alzheimer’s disease 13 Ebastine 5.0 5.0 Anti allergic 14 Esomeprazole Sodium 3.0 3.0 Anti ulcerative Esomeprazole Magnesium 3.0 3.0 Anti ulcerative 15 trihydrate 16 Fexofenadine Hydrochloride 6.0 15.0 Anti histamine 17 Haloperidol 2.0 2.0 Antipsychotic 18 Itopride Hydrochloride 2.0 2.0 Antispasmodics 19 Itraconazole 10.0 10.0 Antifungal 20 Ketrolac Tromethane 2.0 2.0 Anti Inflammatory 21 Lansoprazole 10.0 10.0 Ant ulcerative 22 Loperamide Hydrochloride 10.0 10.0 Anti diarrhea agent 23 Losartan Potassium 6.0 15.0 Anti Hypertensive 24 Nebivolol HCl 2.0 2.0 Anti Hypertensive 25 Nortriptyline HCl 2.0 2.0 Anti depressant 26 Omeprazole 40.0 40.0 Anti ulcerative 27 Omeprazole Sodium 2.0 2.0 Ant ulcerative Omeprazole Magnesium 2.0 2.0 Ant ulcerative 28 Dihydrate 29 Oxatomide 1.0 1.0 Antihistamine Pantoprazole Sodium Sesqui 10.0 20.0 Ant ulcerative 30 Hydrate 31 Pimozide 2.0 2.0 Antipsychotic 32 Pregabalin 2.0 2.0 Epileptic 33 Quetiapine Hemifumarate 2.0 2.0 Antipsychotic Prepared By Rightsource Industrial Solutions Pvt.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • RT² Profiler PCR Array (96-Well Format and 384-Well [4 X 96] Format)
    RT² Profiler PCR Array (96-Well Format and 384-Well [4 x 96] Format) Human Toll-Like Receptor Signaling Pathway Cat. no. 330231 PAHS-018ZA For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® Mastercycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara TP-800 RT² Profiler PCR Array, Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) RT² Profiler PCR Array, Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® RT² Profiler PCR Array, Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (96-well block) Format F RT² Profiler PCR Array, Roche LightCycler 480 (384-well block) Format G RT² Profiler PCR Array, Fluidigm® BioMark™ Format H Sample & Assay Technologies Description The Human Toll-Like Receptor (TLR) Signaling Pathway RT² Profiler PCR Array profiles the expression of 84 genes central to TLR-mediated signal transduction and innate immunity. The TLR family of pattern recognition receptors (PRRs) detects a wide range of bacteria, viruses, fungi and parasites via pathogen-associated molecular patterns (PAMPs). Each receptor binds to specific ligands, initiates a tailored innate immune response to the specific class of pathogen, and activates the adaptive immune response.
    [Show full text]
  • An Immunologist's Perspective on Nutrition, Immunity, and Infectious
    © 2009 Poultry Science Association, Inc. An immunologist’s perspective on nutrition, immunity, and infectious diseases: 1 Introduction and overview M. H. Kogut *2 and K. Klasing † * Southern Plains Agricultural Research Center, USDA-ARS, College Station, TX 77845; and † Department of Avian Sciences, University of California, Davis 95616 Primary Audience: Poultry Nutritionists, Immunologists, Veterinarians, Researchers SUMMARY The immune system is a multifaceted arrangement of membranes (skin, epithelial, and mucus), cells, and molecules whose function is to eradicate invading pathogens or cancer cells from a host. Working together, the various components of the immune system perform a balancing act of being lethal enough to kill pathogens or cancer cells yet specific so as not to cause extensive damage to “self” tissues of the host. A functional immune system is a requirement of a healthy life in modern animal production. Yet infectious diseases still represent a serious drain on the economics (reduced production, cost of therapeutics, and vaccines) and welfare of animal agriculture. The interaction involving nutrition and immunity and how the host deals with infectious agents is a strategic deter- minant in animal health. Almost all nutrients in the diet play a fundamental role in sustaining an op- timal immune response, such that deficient and excessive intakes can have negative consequences on immune status and susceptibility to a variety of pathogens. Dietary components can regulate physiological functions of the body; interacting with the immune response is one of the most im- portant functions of nutrients. The pertinent question to be asked and answered in the current era of poultry production is whether the level of nutrients that maximizes production in commercial diets is sufficient to maintain competence of immune status and disease resistance.
    [Show full text]
  • Ccl17-Dependent Release of Ccl3 Restrains Regulatory T Cells Thereby Aggravating Atherosclerosis
    From the Institute for Cardiovascular Prevention (IPEK) of the Ludwig-Maximilians-Universität München Director: Univ.-Prof. Dr. med. Christian Weber Ccl17-dependent release of Ccl3 restrains regulatory T cells thereby aggravating atherosclerosis Dissertation zum Erwerb des Doctor of Philosophy (Ph.D.) an der Medizinischen Fakultät der Ludwig-Maximilians-Universität München Submitted by M.Sc. Carlos Neideck from Taió in Santa Catarina, Brazil on 21.03.2018 Supervisor: Prof. Dr. med. Christian Weber Second evaluator: Prof. Dr. rer. nat. Jürgen Bernhagen Dean: Prof. Dr. Reinhard Hickel Date of oral defense: 23.07.2018 Affidavit Neideck, Carlos ______________________________________________________________________ Name, Surname ______________________________________________________________________ Street ______________________________________________________________________ Zip Code, Town ______________________________________________________________________ Country I hereby declare, that the submitted thesis entitled: “Ccl17-dependent release of Ccl3 restrains regulatory T cells thereby aggravating atherosclerosis.” is my own work. I have only used the sources indicated and have not made unauthorized use of services of a third party. Where the work of others has been quoted or reproduced, the source is always given. I further declare that the submitted thesis or parts thereof have not been presented as part of an examination degree to any other university. Munich, 25.07.2018 Carlos Neideck Place, date Signature doctoral candidate Confirmation
    [Show full text]
  • Plasma Macrophage-Derived Chemokine (CCL22) and Its
    Egypt J Pediatr Allergy Immunol 2005; 3(1): 20-31. Original article Plasma macrophage-derived chemokine (CCL22) and its receptor CCR4 on peripheral blood T lymphocytes of asthmatic children Background: The macrophage-derived chemokine (MDC/CCL22) acts on Mohamed H. Ezzat, CC chemokine receptor-4 (CCR4) to direct trafficking and recruitment of T Karim Y. Shaheen*. helper-2 (TH2) cells into sites of allergic inflammation. It was previously found overexpressed in lesional samples from adult asthmatics. Objective: This study is aimed to investigate the participation of CCR4/MDC axis in the development of TH2-dominated allergen-induced From the Departments childhood asthma in relation to disease activity, attack severity, and of Pediatrics and response to therapy, and to outline its value in differentiating atopic asthma Clinical Pathology*, from infection-associated airway reactivity. Faculty of Medicine, Methods: Proportion of CCR4-expressing peripheral blood T lymphocytes Ain Shams University, + (CCR4 PBTL%) were purified and quantitated by negative selection from Cairo, Egypt. peripheral blood mononuclear cells by flow cytometry, and the concentration of MDC in plasma was measured by ELISA in 32 children with atopic asthma (during exacerbation and remission), as well as in 12 children with acute lower respiratory tract infections (ALRTI), and 20 healthy children serving as controls. Results: The mean plasma MDC level (925±471.5 pg/ml) and CCR4+PBTL% (55.3±23.6%) were significantly higher in asthmatic children during acute attacks in comparison to children with ALRTI (109±27.3 pg/ml and 27.6±7.5%) and healthy controls (99.6±25.6 pg/ml and 24.2±4.1%).
    [Show full text]
  • The Efficacy of Etanercept As Anti-Breast Cancer Treatment Is
    Shirmohammadi et al. BMC Cancer (2020) 20:836 https://doi.org/10.1186/s12885-020-07228-y RESEARCH ARTICLE Open Access The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages Elnaz Shirmohammadi1, Seyed-Esmaeil Sadat Ebrahimi1, Amir Farshchi2 and Mona Salimi3* Abstract Background: Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha inhibitor that has been investigated for potential antitumor effect in breast cancer with conflicting results. Methods: Secretome data on MDA-MB-231 cancer cell-line were from public repositories and subjected to gene enrichment analyses. Since MDA-MB-231 cells secrete high levels of Granulocyte-Monocyte Colony Stimulating Factor, which activates macrophages to promote tumor growth, the effect of macrophage co-culturing on anticancer efficacy of Etanercept in breast cancer was evaluated using the Boolean network modeling and in vitro experiments including invasion, cell cycle, Annexin PI, and tetrazolium based viability assays and NFKB activity. Results: The secretome profile of MDA-MB-231 cells was similar to the expression of genes following treatment of breast cancer cells with TNF-α. Accordingly, inhibition of TNF-α by Etanercept decreased MDA-MB-231 cell survival, induced apoptosis and cell cycle arrest in vitro and inhibited NFKB activation. The inhibitory effect of Etanercept on cell viability, cell cycle progression, invasion and induction of apoptosis decreased following co-culturing of the cancer cells with macrophages. The Boolean network modeling of the changes in the dynamics of intracellular signaling pathways revealed NFKB activation by secretome of macrophages, leading to a decreased efficacy of Etanercept, suggesting NFKB inhibition as an alternative approach to inhibit cancer cell growth in the presence of macrophage crosstalk.
    [Show full text]